Ascend Advanced Therapies
Private Company
Total funding raised: $29.8M
Overview
Ascend Advanced Therapies is a German CDMO specializing in advanced therapies, formed through the strategic alignment with US-based ABL, Inc. in late 2024. The combined entity provides end-to-end CMC services, from process development to GMP manufacturing and fill-finish, with a particular focus on AAV-based gene therapies. Leveraging over 60 years of combined biologics expertise and proprietary technology to improve vector yields, Ascend aims to be a scalable partner for biotech companies navigating the complex path from bench to clinic.
Technology Platform
Proprietary AAV enhancers for up to 3-fold yield improvement; integrated gene-to-GMP CDMO platform with deep expertise in viral vector (AAV) and cell therapy process development, analytics, and manufacturing, including Oxford Nanopore sequencing for characterization.
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Ascend competes in the fragmented but consolidating advanced therapy CDMO market. It faces competition from large, diversified players like Lonza and Thermo Fisher Scientific, as well as pure-play specialists like Oxford Biomedica, Brammer Bio (part of Thermo Fisher), and Cell and Gene Therapy Catapult. Its differentiators are its combined transatlantic scale post-ABL alignment, deep AAV-specific expertise, and proprietary yield-enhancement technology.